Aytu Biopharma (AYTU) Change in Receivables (2015 - 2026)
Aytu Biopharma (AYTU) posted quarterly Change in Receivables of -$6.4 million for Q1 2026, down 161.25% year-over-year from $10.5 million in Q1 2025, and down 179.5% quarter-over-quarter from -$2.3 million in Q4 2025.
Aytu Biopharma (AYTU) Change in Receivables (2015 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Change in Receivables for 12 consecutive years, with -$6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 161.25% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$11.3 million (down 272.62% YoY), while the FY2025 annual figure was $7.6 million, up 246.68% from the prior year.
- Change in Receivables slipped to -$6.4 million in Q1 2026 per AYTU's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Change in Receivables topped out at $10.5 million in Q1 2025 and bottomed at -$6.4 million in Q1 2026.
- Historically, Change in Receivables has averaged $92235.3 across 5 years, with a median of -$478000.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Receivables tumbled 2775.45% — and 2024, when it jumped 2025.42%.
- Aytu Biopharma's Change in Receivables stood at -$2.4 million in 2022, then surged by 95.04% to -$118000.0 in 2023, then surged by 2025.42% to $2.3 million in 2024, then slumped by 201.32% to -$2.3 million in 2025, then sank by 179.5% to -$6.4 million in 2026.
- Business Quant data shows AYTU's Change in Receivables at -$6.4 million in Q1 2026, -$2.3 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Aytu Biopharma | 24.81 Mn | -1.91 Mn | 7.60 Mn | -6.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.43 Mn |
| Mar 31, 2026 | -6.43 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | -4.67 Mn |
| Jun 30, 2025 | -4.67 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | -478,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Jun 30, 2024 | -5.73 Mn |
| Jun 30, 2024 | -5.73 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Mar 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -118,000.00 |
| Dec 31, 2023 | -118,000.00 |